Table 1.
Epidemiological characteristics, treatment and follow-up of enrolled patients
| Values | |
|---|---|
| Extrauterine LGESS, n (%) | 9 (16.1) |
| Mitotic activity < 5 per 10 high power field, n (%) | 45 (80.4) |
| Immunohistochemical staining, n (%) | |
| Positive estrogen receptor | 51 (91.1) |
| Positive progesterone receptor | 50 (89.3) |
| DFS after first treatment (months), median (range) | 34.7 (5–188) |
| Ages at diagnosis of recurrence (years), median (range) | 43.3 (17–70) |
| Extrapelvic recurrence, n (%) | 23 (41.1) |
| Symptomatic recurrence, n (%) | 23 (41.1) |
| Repeated surgeries for first recurrence, n (%) | 50 (89.3) |
| With residual lesions, n/n (%) | 3/50 (6.0) |
| Chemotherapy for recurrence, n (%) | 17 (30.4) |
| Radiotherapy for recurrence, n (%) | 18 (32.1) |
| Hormone treatment for recurrence, n (%) | 26 (46.4) |
| Fertility sparing | |
| Fertility sparing after first treatment, n (%) | 9 (16.1) |
| Fertility sparing after first recurrence, n (%) | 6 (10.7) |
| Ovarian preservation | |
| Ovarian preservation after first treatment, n (%) | 35 (62.5) |
| Ovarian preservation after first recurrence, n (%) | 9 (16.1) |
| Loss to follow-up, n (%) | 13 (23.2) |
| Repeated recurrence, n/n (%) | 30/43 (69.8) |
| PFI after last treatment for first recurrence (months), median (range) | 18.3 (1–121) |
| Death, n/n (%) | 12/43 (27.9) |
| OS after diagnosis of first recurrence (months), median (range) | 43.6 (3–349) |
DFS, disease-free survival; PFI, progression-free interval; LGESS, low-grade endometrial stromal sarcoma